慶應医学会例会

下記のとおり例会を開催いたしますので、ふるってご来聴くださいますようお願い申し上げます。

日 時 2019 年 12 月 13 日 (金) 17 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Engineering Exhaustion Resistant Stem-cell like T cells to Enhance the Efficacy of Cell Based Therapies

  Madhusudhanan Sukumar Ph.D.
National Cancer Institute (NCI), NIH, Bethesda, MD
Dr. Sukumar has published many excellent studies on memory differentiation and exhaustion of anti-tumor T cells regulated by metabolic reprograming and tumor environments. Everyone interested in T cell therapy and anti-tumor immunity is welcomed.
Selected publications
Cell. 2015 Sep 10;162(6):1206-8.
Cell Metab. 2016 Jan 12;23(1):63-76.
Nature. 2016 ;537(7621):539-543.
Curr Opin Immunol. 2017 Jun; 46:14-22
Cell Metab. 2017 Jul 5;26(1):94-109.
Nature 2017 Aug 31;548(7669):537-542.
Science. 2019 Mar 29;363(6434).
担 当

微生物学・免疫学 教室
責任者:吉村 昭彦 教授
担当者:(内線 61220)

  以上
日 時 2019 年 11 月 19 日 (火) 18 : 00
場 所 JKiC 会議室
演 題

Equilibrium and disruption of host-microbial symbiosis

  Keisuke Chris Nagao M.D., Ph.D.
Cutaneous Leukocyte Biology Section, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
担 当

皮膚科学教室 教室
責任者:天谷 雅行 教授
担当者:高橋 勇人 先生(内線 62411)

  以上
日 時 2019 年 11 月 11 日 (月) 19 : 30
場 所 新教育研究棟2階講堂
演 題

The importance of heart rate control for the treatment of heart failure

  Piotr Ponikowski MD PHD,FESC,FHFA
Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland
担 当

循環器内科 教室
責任者:福田 恵一 教授
担当者:(内線 61420)

  以上
日 時 2019 年 11 月 8 日 (火) 19 : 00
場 所 リサーチパーク1階ラウンジ
演 題

PE management updated ESC PE guideline

  Stavros V Konstantinides MD, PhD
University of Mainz,Germany
担 当

循環器内科 教室
責任者:福田 恵一 教授
担当者:(内線 61420)

  以上
日 時 2019 年 10 月 11 日 (金) 16 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Precision Stimulation Medicine

  Hartwig R Siebner M.D., Ph.D.
Danish Research Centre for Magnetic Resonance
演 題 Transcutaneous spinal stimulation for gait rehabilitation
  Toshiyuki Fujiwara M.D., Ph.D.
Department of Rehabilitation Medicine, Juntendo University School of Medicine / Graduate School of Medicine
演 題 Perspectives of TMS-EEG
  Leo Tomasevic Ph.D.
Danish Research Centre for Magnetic Resonance
演 題 Motor cortex GABAergic dysfunction in Italian patients with Familial adult myoclonic epilepsy (FAME)
  Raffaele Dubbioso M.D., Ph.D.
Department of Neuroscience and Reproductive and Odontostomatological Sciences, University of Naples Federico II
演 題 Effects of multiple sclerosis on TMS outcome measures
  Mads A.J. Madsen Ph.D. student
Danish Research Centre for Magnetic Resonance
演 題 Focal transcranial alternating current stimulation to the sensorimotor hand area at individual alpha and beta rhythm - effects on corticospinal excitability
  Mitsuaki Takemi Ph.D.
Division of Physical and Health Education, Graduate School of Education, The University of Tokyo
担 当

リハビリテーション医学 教室
責任者:里宇明元 教授
担当者:田代祥一 先生(内線 62264)

  以上
日 時 2019 年 9 月 30 日 (月) 18 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Dissecting resistance to PD-1 blockade, one cell at a time

  Drew Mark Pardoll M.D., Ph. D.
Department of Pathology, Johns Hopkins University School of Medicine
  PD-1 pathway blockade has been approved for 16 different cancer types and is being tested in an additional 15. Despite its dramatic activity, the majority of patients do not respond to anti-PD-1 antibodies. We have shown that neoadjuvant anti-PD-1 given to lung cancer patients prior to resection of their primary tumor results in a nearly 50% major pathologic response rate (<10% of tumor bed consisting of viable tumor cells). This clinical format allowed us to obtain large numbers of TIL after anti-PD-1 therapy so that we could perform single cell transcriptomics and TCR repertoire analysis. As part of this analysis we could determine which genes and genetic programs were associated with successful anti-tumor response vs non-response. We found that T cells from non-responding tumors exhibited a broad stress response signature, while T cells from MPR tumors did not. While T cells from both responding and non-responding tumors expressed high levels of PD-1, PD-1+ T cells from non-responding tumors had higher levels of the canonical exhaustion factor TOX and other exhaustion-associated genes, including CD39, Tim3 and other checkpoints. T cells from non-responders demonstrated Treg from non-responding tumors were more numerous and expressed specific Treg inhibitory molecules. Taken together, T cells ronr-responding tumor encounter a high stress microenvironment and express high levels of transcriptional and membrane inhibitory molecules, some of which are therapeutically targetable.
演 題

PD-1 blockade a common denominator for cancer therapy

  Suzanne Louise Topalian M.D.
Department of Surgery and Oncology, Johns Hopkins University School of Medicine
  The PD-1 pathway, including the immune cell receptor Programmed Cell Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates immunosuppression in the tumor microenvironment. Drugs that "release the brakes" on anti-tumor immunity by blocking PD-1 or PD-L1 have shown substantial and durable activity in multiple cancers, validating them as a "common denominator" for cancer therapy. Since September 2014, the US FDA has approved 6 different PD-1/PD-L1 antibodies to treat advanced cancers, including 15 tumor types and the broad genetically-defined MSI-high category. These drugs are now being applied in earlier stages of cancer, in the adjuvant and neoadjuvant settings. Tumor PD-L1 protein expression correlates with enhanced responsiveness of some cancers to anti-PD-1, while tumor mutational burden, reflecting neoantigen load, associates with likelihood of response in additional patients. The continued interrogation of potential biomarkers is expected to further refine the risk:benefit profile for PD-1/PD-L1 antagonists, increase our understanding of the mechanistic underpinnings of this pathway, and guide the development of more effective combination therapies.
担 当

先端研(細胞) 教室
責任者:河上 裕 特任教授
担当者:谷口智憲 先生(内線 62708)

  以上
日 時 2019 年 9 月 24 日 (火) 17 : 00
場 所 臨床研究棟1階ラウンジ
演 題

Angiogenic factors: clinical implications in the management of preeclampsia

  Sofia Cerdeira MD, PhD
Nuffield Department of Obstetrics and Gynaecology, University of Oxford
  Preeclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. Angiogenic factors, in particular soluble fms-like tyrosine kinase 1 (sFlt-1), have emerged as important molecules in the pathogenesis of preeclampsia and are regarded as potential biomarkers and therapeutic targets. We were the first unit in UK to implement sFlt1/PlGF ratio in clinical practice and are helping other units to do so. I will present our latest data and discuss present and future clinical implications on the use of angiogenic factors in the management of preeclampsia.
担 当

産婦人科学(産科学) 教室
責任者:田中 守 教授
担当者:池ノ上 学 先生(内線 62381)

 
  以上
日 時 2019 年 8 月 19 日 (月) 17 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Transcriptional programs underlying T cell exhaustion: Nr4a limits CAR T cell function in solid tumors

  Joyce Chen MD/PhD
La Jolla Institute
参考 固形癌のCAR-T療法におけるT細胞疲弊の分子機構の解明の話。
Nature. 2019 Mar;567(7749):530-534.
NR4A transcription factors limit CAR T cell function in solid tumours.
担 当

微生物学・免疫学教室 教室
責任者:吉村 昭彦 教授
担当者:(内線 61220)

 
  以上
日 時 2019 年 7 月 10 日 (水) 17 : 00
場 所 1号館2階カンファレンスルーム2
演 題

Surgical training and research in the Netherlands

  Bas P.L. Wijnhoven MD PhD
Erasmus University Medical Center Rotterdam The Netherlands
  In contrast to many other countries, training of medical specialists is funded by the Department of Health. The curriculum of medical specialist training including general surgery is well structured and lasts 5-6 years. Specialist (trainers) and hospitals involved in surgical training have been accredited by the Dutch Association of Surgeons. Surgical training includes 4 years of general surgery followed by two years of differentiation in one of the sub-specialities. These are gastrointestinal, oncological, vascular, pediatric and trauma surgery. The training program is competency based: there are key procedures and so called EPA (entrusted professional activities) that are defined to monitor the progress of an individual. Unique in the Dutch system is the quality control and governance of surgical training that will be discussed in my lecture.
The number of positions available for surgical trainees is limited and determined by the government each year. Hence, to enter surgical training has always been very competitive and not easy for young doctors. This is one of the reasons why many students start a PhD program after medical school and to gain experience in basic or clinical research. These young and talented students usually work for 3-4 years full time and are well capable of coordinating trials. This is just one of the reasons that many clinical (randomised) studies come from the Netherlands. Besides this strong academic environment, lack of private practice, strong multidisciplinary working parties and the geographical situation in our small country facilitates multicenter studies. Some more crucial factors for success will be discussed in the lecture.
 
担 当

外科学(一般・消化器) 教室
責任者:北川雄光 教授
担当者:真柳修平 先生(内線 62334)

 
  以上
日 時 2019 年 7 月 8 日 (月) 18 : 30
場 所 リサーチパーク1階 ラウンジ
演 題

Rapidly evolving strategies for the treatment of liver cancer

  Dan G Duda D.M.D., Ph.D.
Massachusetts General Hospital Research Institute, Harvard Medical School
担 当

外科学 教室
責任者:北川 雄光 教授
担当者:茂田 浩平 先生(内線 62234)

 
  以上

†先頭へ

関連病院会 クリニック情報 住所変更依頼 トップページへ戻る